ISOLtake a look at ISOL, recently up over 100%, Great quarterly and great deal with Canopy, This stocks going to rocket, Look at there deal (Pot o Coffee) vs ours (topicals) Both listed below. Its my belief DVA has way more going for it. But then again im basically just talking to myself over here, and there form is buzzing. end of day ISOL will have product on Canopy selves, DVA will have product on Canopy selves,
Isodiol International Inc. Signs Definitive Licensing Agreement with Canopy Growth Corporation for Canadian and International Distribution
20 Jul 2017 13:00 ET
ACCESSWIRE
VANCOUVER, BC / ACCESSWIRE / July 20, 2017 / Isodiol International Inc. (CNSX: ISOL) (OTC PINK: LAGBF) (FSE: LB6A) (the "Company" or "Isodiol") a global cannabis innovator specializing in the development of pharmaceutical and consumer products is pleased to announce it has signed a licensing agreement with Canopy Growth Corporation ("Canopy") (WEED) (https://www.canopygrowth.com).
Canopy Growth is the world's premier cannabis company that operates a collection of diverse brands and curated strain varieties, supported by over half a million square feet of indoor and greenhouse production capacity. Under this licensing agreement, Canopy Growth will have the right to manufacture and distribute the Company's "Pot-O-Coffee" and "Pot-O-Tea" branded marijuana infused single serve K-Cup products in Canada and certain other markets internationally as federal regulations allow. Licensed products include caffeinated and de-caffinated product lines as well as Isodiol's single serve "Pot-O-Coco". In addition to the Canadian rights, Canopy Growth shall have the right of first refusal to sell the "Pot-O" brand products in any territory outside of the US, Mexico and Puerto Rico.
"This distribution agreement has us positioned to increase our global footprint with the largest cannabis company in the world. We will continue to develop our Pot-O-Coffee product lines with ready to drink and cold brew products while working with Canopy Growth for international distribution channels. The Pot-O-Coffee brand is well recognized, and adding additional products to this line will continue to strengthen its market presence," stated Isodiol's CEO Marcos Agramont.
The availability of the various licensed products in Canada and elsewhere will differ depending on applicable laws and regulation. While Canadian law does not yet permit the manufacture and sale of marijuana infused products, the Company anticipates that such products will be permitted in the near future. Furthermore, currently proposed regulations which would permit the sale of infused products, would not allow such products to contain both marijuana and caffeine. As such, the specific product offerings in Canada and elsewhere may be limited. The Company will provide additional updates as regulations are adopted and as product roll-out plans are developed.
About Isodiol International Inc.
Isodiol International, Inc. is the market leader in pharmaceutical grade cannabis compounds and the industry leader in manufacturing and development of consumer products. Isodiol's nutraceutical division is the pioneer of many firsts for Hemp-derived cannabidiol (CBD), including 99% pure crystalline isolate, micro-encapsulation, and nano technology for the highest quality consumable and topical skin care products.
Isodiol's growth strategy includes the development of over-the-counter and pharmaceutical drugs, seeking joint ventures and acquisitions to expand its portfolio of brands and subsidiaries and will aggressively continue International expansion into Latin America, Asia and Europe.
ON BEHALF OF THE BOARD
"Marcos Agramont"
CEO & Director
CORPORATE MEDIA:
ir@isodiol.com
www.isodiol.com
Join Us On Face Book: https://www.facebook.com/isodiol/
Twitter: @isodiol
Forward-Looking Information:This news release contains "forward-looking information" within the meaning of applicable securities laws relating to statements regarding the Company's business, products and future the Company's business, its product offerings and plans for sales and marketing. Although the Company believes that the expectations reflected in the forward looking information are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned to not place undue reliance on forward-looking information. Such forward looking statements are subject to risks and uncertainties that may cause actual results, performance and developments to differ materially from those contemplated by these statements depending on, among other things, the risks that the Company's products and plan will vary from those stated in this news release and the Company may not be able to carry out its business plans as expected. Except as required by law, the Company expressly disclaims any obligation, and does not intend, to update any forward looking statements or forward-looking information in this news release. Although the Company believes that the expectations reflected in the forward looking information are reasonable, there can be no assurance that such expectations will prove to be correct and makes no reference to profitability based on sales reported. The statements in this news release are made as of the date of this release.
The CSE has not reviewed, approved or disapproved the content of this press release.
SOURCE: Isodiol International Inc.
https://www.accesswire.com/img.ashx?id=468963
Smiths Falls, ON – Canopy Growth Corporation (Canopy Growth) (TSX:CGC) has entered into an agreement with Delivra Inc. (Delivra) (TSX.V:DVA) to supply Canopy Growth’s operating subsidiaries, including Tweed Inc. and Bedrocan Canada Inc., with cannabis-infused topical product formulations.
Topical cannabis products have proven market demand but have yet to be created for the legal medical cannabis market in Canada. By teaming with Delivra, Tweed will be able to offer customers a unique product suite, produced to exacting standards and presented alongside a wide and growing range of cannabis options. Delivra has created a new topical formulation for this express purpose, to be made exclusively available in Canada from Tweed.
“Our product lines are about variety,” said Bruce Linton, Chairman and CEO of Canopy Growth. “Increasingly, variety means more than dried cannabis strains. It means lotions, pills, and other forms of cannabinoid delivery that don’t involve inhaling smoke. Delivra has built a reputation for innovative and proven leadership in transdermal applications and we’re pleased to be working with them to provide a best-in-class cannabis delivery solution for our Canadian customers.”
Delivra and Canopy Growth are also collaborating on a series of studies to reinforce the body of scientific evidence surrounding the transdermal application of cannabinoids. The companies anticipate that transdermal cannabinoids could be an effective therapeutic option for a range of conditions.
“Cannabinoid therapy is a rapidly emerging field of medicine, quickly demonstrating its applicability to a range of acute and chronic indications, in particular those related to pain management”, said Dr. Joe Gabriele, founder and CEO of Delivra. “We are very pleased to be working with Canopy Growth, the Canadian market leader, to provide innovative topical solutions, both for localized and systemic delivery, according to the need of the patient and the condition.”
Here’s to Future Growth.
About Canopy Growth Corporation
Canopy Growth is a world-leading diversified cannabis company, offering diverse brands and curated cannabis strain varieties in dried and oil extract forms. Through its wholly-owned subsidiaries, Tweed, Tweed Farms, and Bedrocan Canada, Canopy Growth operates three state-of-the-art production facilities with over half a million square feet of indoor and greenhouse production capacity. Canopy Growth has established partnerships with leading sector names in Canada and abroad. For more information, www.canopygrowth.com.
About Delivra
Delivra is a developer of transdermal technologies for the delivery of pharmaceutical and natural molecules, through the skin, rather than via pills. Delivra manufactures and sells a growing line of natural topical creams under the LivReliefTM brand, for conditions such as joint and muscle pain, nerve pain, varicose veins, wound healing, and sports performance. LivRelief products are available in pharmacies, grocery chains, and independent health food stores across Canada, and on-line at www.livrelief.com. LivRelief products were launched for on-line sales in the United States in Q4 2015. In parallel with its consumer products business, Delivra also has a mandate to license its unique, proven, and patent-pending delivery platform to global pharmaceutical companies for the transdermal delivery of third party active ingredients to treat a broad range of conditions. With a global transdermal drug delivery market forecast to grow to USD $40 billion by 2018 (Source: Kelly Scientific), Delivra believes the licensing opportunity is robust. Delivra is headquartered in Burlington, Ontario and has a research and development laboratory in Charlottetown, PEI.
Notice Regarding Forward Looking Statements
This news release contains forward-looking statements. Often, but not always, forward-looking statements can be identified by the use of words such as “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Canopy Growth Corporation, Tweed Inc., Tweed Farms Inc. or Bedrocan Canada Inc. to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Examples of such statements include future operational and production capacity, the impact of enhanced infrastructure and production capabilities, and forecasted available product selection. The forward-looking statements included in this news release are made as of the date of this news release and Canopy Growth Corp. does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.
Neither the TSX Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Exchange) accepts responsibility for the adequacy or accuracy of this release.
Contact:
Jordan Sinclair
Director of Communications
Jordan@tweed.com
613-769-4196
Tyler Burns
Investor Relations
Canopy Growth Corporation
Tyler.burns@canopygrowth.com
1-855-558-9333 ex 122
Nicole Marchand
Investor Relations
Delivra Corp.
ir@delivrainc.com
416-428-3533
Chris Schnarr
President and CFO
Delivra Corp.
cschnarr@delivrainc.com
905-639-7878